Liquid Biopsy Assays For ctDNA Detection

In recent years, liquid biopsies have rapidly evolved and have had a dramatic impact on the field of clinical oncology. Most importantly, their non-invasive nature enables clinicians to isolate, continuously monitor and analyze genetic material circulating around the body including circulating tumor DNA (ctDNA), without any additional complications for the patient. For translational scientists, assays which enable sensitive and accurate detection of patient ctDNA can accelerate the progression of targeted therapies into the clinic and ensure the best treatment decisions are made for patients.

Download the Infographic

This detailed and complimentary infographic outlines a case study of how developers can select an appropriate Liquid Biopsy Assay for ctDNA Detection using Beacon Biomarkers & Assays.

Download Now

Find out more

The selection of biomarkers and assays is of utmost importance as it directly impacts the accuracy and efficacy of diagnostic and treatment strategies.

By carefully selecting appropriate biomarkers and assays, researchers can drive advancements in cancer care, leading to earlier detection, more precise diagnosis, targeted therapies, and improved patient outcomes. Beacon are here to support you in making these decisions with confidence through our encompassing database solution.

Discover a database tailored to your needs

Speak with our Team

Our dedicated account and research teams can help you with any questions you have by demonstrating how this insight and data is collated on Beacon Biomarkers & Assays.

Get Started